Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis Cardiol Therapeutics Inc January 9, 2024
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis Cardiol Therapeutics Inc November 1, 2023
Open Orphan expands human challenge trial capacity with new volunteer recruitment centres Open Orphan Plc January 20, 2021
Open Orphan has a great start to 2021 with key 12-month contract renewal Open Orphan Plc January 6, 2021
Open Orphan wins vaccine contract extension and announces toxicology study completion Open Orphan Plc December 23, 2020
